List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7632919/publications.pdf Version: 2024-02-01



FRIC LONASCH

#	Article	IF	CITATIONS
1	Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International, 2022, 129, 610-620.	2.5	22
2	Gene Body Methylation of the Lymphocyte-Specific Gene <i>CARD11</i> Results in Its Overexpression and Regulates Cancer mTOR Signaling. Molecular Cancer Research, 2022, 19, 1917-1928.	3.4	3
3	Sunitinibâ€Related Osteonecrosis of the External Auditory Canal: Case Report. Otolaryngology - Head and Neck Surgery, 2022, 167, 607-608.	1.9	3
4	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. Cancers, 2022, 14, 644.	3.7	11
5	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 71-90.	4.9	248
6	Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. European Urology Open Science, 2022, 37, 3-6.	0.4	4
7	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	7.0	12
8	A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science Translational Medicine, 2022, 14, eabm6420.	12.4	29
9	VHL-P138R and VHL-L163R Novel Variants: Mechanisms of VHL Pathogenicity Involving HIF-Dependent and HIF-Independent Actions. Frontiers in Endocrinology, 2022, 13, 854365.	3.5	0
10	Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 808-824.	3.8	2
11	Evaluation, diagnosis and surveillance of renal masses in the setting of VHL disease. World Journal of Urology, 2021, 39, 2409-2415.	2.2	28
12	Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nature Reviews Nephrology, 2021, 17, 245-261.	9.6	278
13	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology,the, 2021, 9, 13-21.	11.4	37
14	Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) Journal of Clinical Oncology, 2021, 39, 333-333.	1.6	3
15	Somatic Copy Number Alterations and Associated Genes in Clear-Cell Renal-Cell Carcinoma in Brazilian Patients. International Journal of Molecular Sciences, 2021, 22, 2265.	4.1	12
16	The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study Journal of Clinical Oncology, 2021, 39, 273-273.	1.6	19
17	Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers, 2021, 13, 1475.	3.7	10
18	Combination antiangiogenic tyrosine kinase inhibition and antiâ€PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Medicine, 2021, 10, 2341-2349.	2.8	15

#	Article	IF	CITATIONS
19	Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist, 2021, 26, 476-482.	3.7	19
20	Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers, 2021, 13, 2170.	3.7	15
21	Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nature Medicine, 2021, 27, 802-805.	30.7	151
22	MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell car cell renal cell carcinoma. Expert Opinion on Investigational Drugs, 2021, 30, 495-504.	4.1	24
23	Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell, 2021, 184, 2988-3005.e16.	28.9	166
24	Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 790.e17-790.e23.	1.6	3
25	Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. , 2021, 9, e002850.		15
26	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. Cancer, 2021, 127, 3957-3966.	4.1	11
27	Tumor diameter response in patients with metastatic clear cell renal cell carcinoma is associated with overall survival. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 837.e9-837.e17.	1.6	3
28	Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers. Science Translational Medicine, 2021, 13, eabe6201.	12.4	19
29	Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncology, The, 2021, 22, 1732-1739.	10.7	84
30	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nature Communications, 2021, 12, 6375.	12.8	22
31	Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease. New England Journal of Medicine, 2021, 385, 2036-2046.	27.0	274
32	Exposure-response modeling of cabozantinib in patients with renal cell carcinoma: Implications for patient care. Cancer Treatment Reviews, 2020, 89, 102062.	7.7	14
33	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open, 2020, 5, e001073.	4.5	1
34	PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma. Nature Communications, 2020, 11, 2135.	12.8	114
35	Chronic hepatitis C virus infection and genitourinary cancers: A case-control study. Seminars in Oncology, 2020, 47, 165-167.	2.2	0
36	Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer. Clinical Cancer Research, 2020, 26, 4970-4982.	7.0	45

#	Article	IF	CITATIONS
37	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. British Journal of Cancer, 2020, 123, 898-904.	6.4	36
38	Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer. Cancer Cell, 2020, 37, 371-386.e12.	16.8	68
39	Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist, 2020, 25, 252-258.	3.7	62
40	Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau disease–associated renal cell carcinoma Journal of Clinical Oncology, 2020, 38, 5003-5003.	1.6	40
41	Phase I/II study of the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC) Journal of Clinical Oncology, 2020, 38, 611-611.	1.6	33
42	Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma. JCO Oncology Practice, 2020, 16, e1264-e1271.	2.9	16
43	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1160-1170.	4.9	163
44	SET-ing the stage for PI3Kβ inhibitor sensitivity in clear cell renal cell carcinoma. Oncotarget, 2019, 10, 1540-1541.	1.8	0
45	MTHFD2 links RNA methylation to metabolic reprogramming in renal cell carcinoma. Oncogene, 2019, 38, 6211-6225.	5.9	78
46	Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, 451-456.	1.9	7
47	Hypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras–ERK Pathway Activation in Hypoxia. Molecular Cancer Research, 2019, 17, 1220-1232.	3.4	22
48	Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e526-e533.	1.9	9
49	Durable complete response in renal cell carcinoma clinical trials. Lancet, The, 2019, 393, 2362-2364.	13.7	7
50	SETD2 regulates the maternal epigenome, genomic imprinting and embryonic development. Nature Genetics, 2019, 51, 844-856.	21.4	207
51	Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist, 2019, 24, 491-497.	3.7	22
52	Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nature Metabolism, 2019, 1, 431-444.	11.9	158
53	Sources of Frustration Among Patients Diagnosed With Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 11.	2.8	11
54	Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Communications Biology, 2019, 2, 386.	4.4	81

#	Article	IF	CITATIONS
55	A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx) Journal of Clinical Oncology, 2019, 37, 4501-4501.	1.6	9
56	An open-label phase II study to evaluate PT2977 for the treatment of von Hippel-Lindau disease-associated renal cell carcinoma Journal of Clinical Oncology, 2019, 37, TPS680-TPS680.	1.6	7
57	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1278-1285.	4.9	185
58	Renal cell carcinoma brain metastasis with pseudoprogression and radiation necrosis on nivolumab after previous treatment with stereotactic radiosurgery: An illustrative case report and review of the literature. Practical Radiation Oncology, 2018, 8, e262-e265.	2.1	8
59	Interconnection: A qualitative analysis of adjusting to living with renal cell carcinoma. Palliative and Supportive Care, 2018, 16, 146-154.	1.0	5
60	Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e47-e57.	1.9	12
61	BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast Differentiation. Neoplasia, 2018, 20, 32-43.	5.3	13
62	Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2018, 36, 1588-1593.	1.6	39
63	Pazopanib in patients with von Hippel-Lindau disease: a single-arm, single-centre, phase 2 trial. Lancet Oncology, The, 2018, 19, 1351-1359.	10.7	63
64	Updates to the Management of Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 639-641.	4.9	29
65	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science, 2018, 361, 290-295.	12.6	134
66	AKT isoform-specific expression and activation across cancer lineages. BMC Cancer, 2018, 18, 742.	2.6	32
67	Preventive medicine of von Hippel–Lindau disease-associated pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2018, 25, 783-793.	3.1	42
68	A first-in-human phase 1 dose-escalation trial of the oral HIF-2a inhibitor PT2977 in patients with advanced solid tumors Journal of Clinical Oncology, 2018, 36, 2508-2508.	1.6	21
69	Homologous repair deficiency in VHL-mutated clear cell renal cell carcinoma Journal of Clinical Oncology, 2018, 36, 585-585.	1.6	3
70	Pilot study of dovitinib in patients with von Hippel-Lindau disease. Oncotarget, 2018, 9, 23390-23395.	1.8	15
71	Examination of moderators of expressive writing in patients with renal cell carcinoma: the role of depression and social support. Psycho-Oncology, 2017, 26, 1361-1368.	2.3	22
72	Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clinical Genitourinary Cancer, 2017, 15, 363-370.	1.9	17

#	Article	IF	CITATIONS
73	Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. Journal of Urology, 2017, 198, 530-537.	0.4	55
74	Incorporating New Systemic Therapies in Kidney Cancer Treatment. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 703-705.	4.9	4
75	Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell Carcinoma. Targeted Oncology, 2017, 12, 333-340.	3.6	5
76	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. BJU International, 2017, 120, 782-792.	2.5	68
77	Programmed cell death ligand 1 and tumorâ€infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer, 2017, 123, 4823-4831.	4.1	79
78	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 804-834.	4.9	443
79	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	1.9	36
80	Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape. Clinical Cancer Research, 2017, 23, 6686-6696.	7.0	66
81	HNF1B Loss Exacerbates the Development of Chromophobe Renal Cell Carcinomas. Cancer Research, 2017, 77, 5313-5326.	0.9	19
82	Outcomes of Patients With Metastatic Non–Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clinical Genitourinary Cancer, 2017, 15, e205-e208.	1.9	24
83	Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening. BMC Genomics, 2017, 18, 678.	2.8	24
84	Systematic Review: Perioperative Systemic Therapy for Metastatic Renal Cell Carcinoma. Kidney Cancer, 2017, 1, 57-64.	0.4	8
85	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, 2017, 35, 2993-3001.	1.6	145
86	Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget, 2017, 8, 42149-42158.	1.8	6
87	Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU International, 2016, 117, 761-765.	2.5	56
88	NCCN Evidence Blocks. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 616-619.	4.9	44
89	Evaluation and management of pancreatic lesions in patients with von Hippel–Lindau disease. Nature Reviews Clinical Oncology, 2016, 13, 537-549	27.6	72
90	Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 499-503.	1.9	39

#	Article	IF	CITATIONS
91	The use of spine stereotactic radiosurgery for oligometastatic disease. Journal of Neurosurgery: Spine, 2016, 25, 239-247.	1.7	43
92	Key considerations in the treatment of von Hippel-Lindau disease. Future Oncology, 2016, 12, 1755-1758.	2.4	3
93	The Role of Metastasectomy in Patients with Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: A Matched Controlled Analysis. Journal of Urology, 2016, 196, 678-684.	0.4	24
94	Treatment of Relapsed Germ Cell Tumors: Time For Something New?. Journal of Oncology Practice, 2016, 12, 449-450.	2.5	1
95	Dual Chromatin and Cytoskeletal Remodeling by SETD2. Cell, 2016, 166, 950-962.	28.9	204
96	Outcomes of unselected patients with metastatic clear-cell renal cell carcinoma treated with first-line pazopanib therapy followed by vascular endothelial growth factor receptor tyrosine kinase inhibitors or mammalian target of rapamycin inhibitors: a sin. BJU International, 2016, 118, 264-271.	2.5	17
97	Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review. Current Medical Research and Opinion, 2016, 32, 741-747.	1.9	12
98	Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. European Urology, 2016, 69, 866-874.	1.9	272
99	Autophagy degrades hypoxia inducible factors. Molecular and Cellular Oncology, 2016, 3, e1104428.	0.7	12
100	Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. European Urology, 2016, 70, 348-357.	1.9	111
101	Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US. Journal of Medical Economics, 2016, 19, 462-468.	2.1	7
102	Prognosticators and outcomes of patients with renal cell carcinoma and adjacent organ invasion treated with radical nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 237.e19-237.e26.	1.6	13
103	The radiogenomic risk score stratifies outcomes in a renal cell cancer phase 2 clinical trial. European Radiology, 2016, 26, 2798-2807.	4.5	33
104	Loss of histone H3 lysine 36 trimethylation is associated with an increased risk of renal cell carcinoma-specific death. Modern Pathology, 2016, 29, 34-42.	5.5	55
105	Fast clearance of lipid droplets through MAP1S-activated autophagy suppresses clear cell renal cell carcinomas and promotes patient survival. Oncotarget, 2016, 7, 6255-6265.	1.8	40
106	Kidney Cancer, Version 3.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 151-159.	4.9	198
107	Testicular Cancer, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 772-799.	4.9	98
108	Kidney Cancer: Current and Novel Treatment Options. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 679-681.	4.9	0

#	Article	IF	CITATIONS
109	Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 427.e17-427.e23.	1.6	35
110	The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma. BMC Cancer, 2015, 15, 304.	2.6	16
111	Dysregulation of HIF2α and autophagy in renal cell carcinoma. Molecular and Cellular Oncology, 2015, 2, e965643.	0.7	3
112	Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, nonâ€sarcomatoid renal carcinomas. Journal of Pathology: Clinical Research, 2015, 1, 212-224.	3.0	12
113	Posttraumatic stress and depressive symptoms in renal cell carcinoma: association with quality of life and utility of single-item distress screening. Psycho-Oncology, 2015, 24, 1477-1484.	2.3	23
114	Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1017-1029.	3.4	159
115	Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Modern Pathology, 2015, 28, 1225-1235.	5.5	23
116	Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. Annals of Oncology, 2015, 26, 1300-1304.	1.2	39
117	Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 166.e21-166.e29.	1.6	44
118	The PI3K/AKT Pathway and Renal Cell Carcinoma. Journal of Genetics and Genomics, 2015, 42, 343-353.	3.9	267
119	Surgical Management of Local Retroperitoneal Recurrence of Renal Cell Carcinoma after Radical Nephrectomy. Journal of Urology, 2015, 194, 316-322.	0.4	49
120	Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States. Expert Opinion on Pharmacotherapy, 2015, 16, 805-819.	1.8	7
121	First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting. Clinical Genitourinary Cancer, 2015, 13, 210-217.	1.9	23
122	Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Nonâ€Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial. Oncologist, 2015, 20, 1140-1148.	3.7	13
123	The Radiogenomic Risk Score: Construction of a Prognostic Quantitative, Noninvasive Image-based Molecular Assay for Renal Cell Carcinoma. Radiology, 2015, 277, 114-123.	7.3	61
124	Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma. Cancer Research, 2015, 75, 316-329.	0.9	34
125	Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. Journal of Behavioral Medicine, 2015, 38, 48-56.	2.1	15
126	Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices. Current Medical Research and Opinion, 2014, 30, 2041-2050.	1.9	37

#	Article	IF	CITATIONS
127	Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Current Medical Research and Opinion, 2014, 30, 2343-2353.	1.9	13
128	Mammalian target of rapamycin (<scp>mTOR</scp>) inhibitorâ€associated nonâ€infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU International, 2014, 113, 376-382.	2.5	48
129	Axitinib for the Treatment of Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 397-403.	1.3	23
130	Clinical Outcomes for Patients with Metastatic Renal Cell Carcinoma Treated with Alternative Sunitinib Schedules. Journal of Urology, 2014, 191, 611-618.	0.4	122
131	Outcomes of Patients With Metastatic Renal Cell Carcinoma and End-Stage Renal Disease Receiving Dialysis and Targeted Therapies: A Single Institution Experience. Clinical Genitourinary Cancer, 2014, 12, 348-353.	1.9	36
132	Partial Nephrectomy in the Setting of Metastatic Renal Cell Carcinoma. Journal of Urology, 2014, 192, 36-42.	0.4	12
133	Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. Cancer Research, 2014, 74, 3127-3136.	0.9	20
134	Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Research, 2014, 24, 241-250.	5.5	160
135	Renal cell carcinoma. BMJ, The, 2014, 349, g4797-g4797.	6.0	509
136	Clear cell papillary renal cell carcinoma in patients with von Hippel-Lindau syndrome—clinicopathological features and comparative genomic analysis of 3 cases. Human Pathology, 2014, 45, 1966-1972.	2.0	31
137	Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer, 2014, 120, 1794-1799.	4.1	154
138	Genetic Kidney Cancer Syndromes. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1347-1355.	4.9	26
139	Kidney Cancer, Version 2.2014. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 175-182.	4.9	56
140	Cadherin-11 in Renal Cell Carcinoma Bone Metastasis. PLoS ONE, 2014, 9, e89880.	2.5	31
141	Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncology, The, 2013, 14, 1233-1242.	10.7	215
142	Molecular Markers to Predict Response to Therapy. Seminars in Oncology, 2013, 40, 444-458.	2.2	18
143	Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. European Urology, 2013, 63, 1122-1127.	1.9	88
144	Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 450-454.	1.3	7

#	Article	IF	CITATIONS
145	The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 620-624.	1.3	49
146	Tumor-Specific Isoform Switch of the Fibroblast Growth Factor Receptor 2 Underlies the Mesenchymal and Malignant Phenotypes of Clear Cell Renal Cell Carcinomas. Clinical Cancer Research, 2013, 19, 2460-2472.	7.0	72
147	Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU International, 2013, 111, 997-1005.	2.5	22
148	Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chinese Journal of Cancer, 2013, 32, 303-311.	4.9	19
149	Chemotherapy, Targeted Therapies, and Biological Therapies for Renal Cell Carcinoma. , 2013, , 713-725.		0
150	Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis. Journal of Biomolecular Screening, 2012, 17, 572-580.	2.6	23
151	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 502-535.	4.9	71
152	Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients. Clinical Cancer Research, 2012, 18, 3961-3971.	7.0	138
153	A Phase 2 Trial of Sunitinib in Patients with Advanced Non–clear Cell Renal Cell Carcinoma. European Urology, 2012, 62, 1013-1019.	1.9	139
154	Renal Tumors. , 2012, , 287-309.		0
155	An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Science, 2012, 10, 56.	1.7	59
156	State of the Science: An Update on Renal Cell Carcinoma. Molecular Cancer Research, 2012, 10, 859-880.	3.4	142
157	Pazopanib therapy for cerebellar hemangioblastomas in von Hippel–Lindau disease. Targeted Oncology, 2012, 7, 145-149.	3.6	34
158	Ten Years of Progress in Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 690-693.	4.9	10
159	Presurgical Therapy in Renal Cell Carcinoma. , 2012, , 241-247.		0
160	Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC) Journal of Clinical Oncology, 2012, 30, 368-368.	1.6	1
161	Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. Journal of Urology, 2011, 185, 439-444.	0.4	113
162	Clinical genomics of renal epithelial tumors. Cancer Genetics, 2011, 204, 285-297.	0.4	80

#	Article	IF	CITATIONS
163	Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma. Current Clinical Pharmacology, 2011, 6, 189-198.	0.6	12
164	Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. Current Clinical Pharmacology, 2011, 6, 144-150.	0.6	13
165	Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU International, 2011, 107, 741-747.	2.5	27
166	A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU International, 2011, 108, 679-686.	2.5	54
167	Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2011, 59, 10-15.	1.9	98
168	Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. European Urology, 2011, 60, 964-971.	1.9	89
169	Pilot Trial of Bone-Targeted Therapy Combining Zoledronate With Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2011, 9, 81-88.	1.9	18
170	Have Molecularly Targeted Therapies Improved Overall Survival in Renal Cell Carcinoma?. Current Oncology Reports, 2011, 13, 153-156.	4.0	1
171	Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer, 2011, 117, 4958-4965.	4.1	48
172	Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncology, 2011, 7, 1247-1253.	2.4	28
173	Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Modern Pathology, 2011, 24, 1470-1479.	5.5	101
174	Systemic therapy for sarcomatoid renal cell carcinoma. Expert Review of Anticancer Therapy, 2011, 11, 913-920.	2.4	8
175	Durable Remission of Metastatic Renal Cell Carcinoma With Gemcitabine and Capecitabine After Failure of Targeted Therapy. Journal of Clinical Oncology, 2011, 29, e203-e205.	1.6	17
176	Pilot trial of sunitinib therapy in patients with von Hippel–Lindau disease. Annals of Oncology, 2011, 22, 2661-2666.	1.2	96
177	Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and lowâ€dose interferon alfa in patients with advanced renal cell carcinoma. Cancer, 2010, 116, 57-65.	4.1	105
178	Targeted therapy for locally advanced renal cell carcinoma. Targeted Oncology, 2010, 5, 113-118.	3.6	5
179	Prognostic and Predictive Factors in the Targeted Therapy Era: Filling in the Blanks. Current Oncology Reports, 2010, 12, 143-145.	4.0	0
180	Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. European Urology, 2010, 58, 819-828.	1.9	89

ERIC JONASCH

#	Article	IF	CITATIONS
181	Vascular endothelial growth factorâ€ŧargeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer, 2010, 116, 5219-5225.	4.1	121
182	Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Annals of Oncology, 2010, 21, 1599-1606.	1.2	41
183	1661 DOES TARGETED THERAPY RESULT IN RELIABLE AND MEANINGFUL PRIMARY TUMOR DOWNSTAGING IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA?. Journal of Urology, 2010, 183, .	0.4	2
184	Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment. Journal of Urology, 2010, 184, 1877-1881.	0.4	67
185	Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Review of Anticancer Therapy, 2010, 10, 1883-1889.	2.4	9
186	Papillary Renal Cell Carcinoma: Radiologic-Pathologic Correlation and Spectrum of Disease. Radiographics, 2009, 29, 741-754.	3.3	123
187	Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma. Clinical Cancer Research, 2009, 15, 81-90.	7.0	54
188	Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2009, 27, 4076-4081.	1.6	183
189	Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 386-391.	3.6	120
190	Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon. Cancer, 2009, 115, 1859-1866.	4.1	30
191	Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer, 2009, 115, 2346-2354.	4.1	25
192	Prognostic models. Cancer, 2009, 115, 2028-2030.	4.1	3
193	Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU International, 2009, 104, 456-460.	2.5	53
194	Randomized Trial of Adjuvant Thalidomide Versus Observation in Patients With Completely Resected High-Risk Renal Cell Carcinoma. Urology, 2009, 73, 337-341.	1.0	32
195	Cutaneous Squamous Cell Carcinoma and Inflammation of Actinic Keratoses Associated with Sorafenib. Clinical Genitourinary Cancer, 2009, 7, 20-23.	1.9	103
196	Kidney Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 618-630.	4.9	249
197	Testicular Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 672-693.	4.9	103
198	Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Current Oncology Reports, 2008, 10, 253-258.	4.0	9

#	Article	IF	CITATIONS
199	Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer, 2008, 113, 72-77.	4.1	40
200	Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. British Journal of Cancer, 2008, 98, 1336-1341.	6.4	61
201	Patterns of intervention for renal lesions in von Hippel‣indau disease. BJU International, 2008, 102, 940-945.	2.5	32
202	A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents. Journal of Urology, 2008, 180, 867-872.	0.4	54
203	Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma. Journal of Urology, 2008, 180, 94-98.	0.4	157
204	A Novel Von Hippel–Lindau Point Mutation Presents as Apparently Sporadic Pheochromocytoma. Cancer Investigation, 2008, 26, 642-646.	1.3	2
205	Inhibition of Mxi1 suppresses HIF-2α-dependent renal cancer tumorigenesis. Cancer Biology and Therapy, 2008, 7, 1619-1627.	3.4	16
206	Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass), 2008, 14, 315-319.	2.0	16
207	Presurgical therapy in metastatic renal cell carcinoma. Expert Review of Anticancer Therapy, 2007, 7, 73-78.	2.4	13
208	Cytoreductive Nephrectomy for T4NxM1 Renal Cell Carcinoma: The M.D. Anderson Cancer Center Experience. Urology, 2007, 69, 835-838.	1.0	23
209	Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer, 2006, 106, 2143-2147.	4.1	15
210	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-Î ³ for metastatic renal cell carcinoma. Cancer, 2006, 107, 497-505.	4.1	14
211	Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-1±-2b. Cancer, 2006, 107, 2254-2261.	4.1	38
212	Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Research, 2005, 15, 77-82.	1.2	108
213	Port-Site Metastasis: The Influence of Biology. European Urology, 2005, 47, 357-360.	1.9	21
214	Percutaneous Radiofrequency Ablation of Renal Tumors: Technique, Complications, and Outcomes. Journal of Vascular and Interventional Radiology, 2005, 16, 679-688.	0.5	109
215	Lysophosphatidic acid production and action: Validated targets in cancer?. Journal of Cellular Biochemistry, 2004, 92, 1115-1140.	2.6	91
216	Melanoma of unknown primary: experience at the dana farber-partners cancer center and review of the literature. Journal of the American Academy of Dermatology, 2004, 50, P6.	1.2	0

#	Article	IF	CITATIONS
217	Melanoma: what the primary care physician needs to know. Primary Care Update for Ob/Gyns, 2003, 10, 51-59.	0.1	0
218	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood, 2003, 102, 3829-3836.	1.4	143
219	Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities. Oncologist, 2001, 6, 34-55.	3.7	478
220	Melanoma vaccination: state-of-the-art and experimental approaches. Expert Review of Anticancer Therapy, 2001, 1, 427-440.	2.4	1
221	Ras- and Raf-induced Down-modulation of Non-muscle Tropomyosin Are MEK-independent. Journal of Biological Chemistry, 1998, 273, 32182-32186.	3.4	34